Conjugates of an anti-TNF-alpha antibody
View Patent ↗Conjugates of an anti-TNF antibody and one or more nonpeptidic water-soluble polymers are provided. Typically, the nonpeptidic water-soluble polymer is poly(ethylene glycol) or a derivative thereof. Also provided, among other things, are compositions comprising conjugates, methods of making conjugates, and methods of administering compositions to a patient.
1. A composition comprising:
(i) a conjugate comprising a single water-soluble polymer that is a polyethylene glycol terminally capped with a methoxy group and having a weight-average molecular weight in the range of from about 10,000 daltons to about 100,000 daltons covalently attached, either directly or through a spacer moiety of one to twenty atoms, to an amino group of an amino acid side chain or an N-terminal amine of a full length anti-TNFα antibody that is neither galactosylated nor glycosylated, wherein the one to twenty atoms within the spacer moiety, when present, include the covalent attachment to the amino group of the full length anti-TNFα antibody and atoms derived from a water-soluble polymer reagent used to attach the water-soluble polymer to the full length anti-TNFα antibody; and
(ii) a pharmaceutically acceptable excipient,
wherein at least about 95% of the conjugates in the composition have a single water soluble polymer attached to the full length anti-TNFα antibody.
2. The composition of claim 1 , wherein at least 99% of the conjugates in the composition have a single water soluble polymer attached to the full length anti-TNFα antibody.
3. The composition of claim 1 , free of albumin.
4. The composition of claim 2 , containing from about 15 to about 95% by weight of the pharmaceutically acceptable excipient.
5. The composition of claim 2 , in the form of a powder suitable for reconstitution as a liquid.
6. The composition of claim 5 , wherein the powder is a lyophilate.
7. The composition of claim 2 , in the form of a liquid.
8. The composition of claim 7 , wherein the liquid is a solution or suspension.
9. The composition of claim 2 , in unit dosage form.
10. The composition of claim 2 , wherein the water-soluble polymer is branched.
11. The composition of claim 2 , wherein the water-soluble polymer is linear.
12. The composition of claim 2 , wherein the full length anti-TNFα antibody is not a dimer or trimer.
13. The composition of claim 2 , wherein the full length anti-TNFα antibody is monovalent.
14. The composition of claim 2 , wherein the full length anti-TNFα antibody is not CDR-grafted.
15. The composition of claim 2 , wherein the conjugate has the structure:
wherein POLY is the water-soluble polymer; (a) is zero or one; X, when present, is the spacer moiety; R 1 is H or an organic radical having 1 to 3 carbon atoms; and ATA is the full length anti-TNFα antibody.
16. The composition of claim 2 , wherein the conjugate has the structure:
wherein POLY is the water-soluble polymer; X, when present, is the spacer moiety; (a) is either zero or one; (j) is zero or an integer from 1 to about 20; (b) is zero or an integer from 1 to about 10; each R 2 , when present, is H or an organic radical; each R 3 , when present, is H or an organic radical; and ATA the full length anti-TNFα antibody.
17. The composition of claim 15 , wherein the conjugate has the structure:
wherein n ranges from about 225 to about 1930.
18. The composition of claim 15 , having the structure:
wherein n ranges from about 225 to about 1930.
19. The composition of claim 1 , wherein the poly(ethylene glycol) has a weight-average molecular weight in the range of from about 10,000 Daltons to about 85,000 Daltons.
20. The composition of claim 1 , wherein the anti-TNFα antibody is either infliximab or adalimumab.